Abstract: A method of determining a potential of a diabetic patient to benefit from anti oxidant therapy for treatment of a vascular complication, the method comprising determining a haptoglobin phenotype of the diabetic patient and thereby determining the potential of the diabetic patient to benefit from said anti oxidant therapy, whereby a patient having a haptoglobin 2-2 phenotype benefits from anti oxidant therapy more than a patient having a haptoglobin 1-2 phenotype or a patient having a haptoglobin 1-1 phenotype.

Abstract: A method of diagnosing Type 1 Diabetes Mellitus (T1DM) in a subject in need thereof is provided. The method comprising determining a presence and/or a level of antibodies in a biological sample of the subject, wherein the presence or level above a predetermined threshold is indicative of T1DM, thereby diagnosing T1DM in the subject. Also provided are a kit for diagnosing T1DM and a method of monitoring anti diabetic treatment.

Abstract: The present invention provides novel peptides, nucleic acids, compounds, compositions and methods for regulating apoptosis, and screening methods for identifying same. Regulation of apoptosis is mediated via IAPi-derived proteins, peptide fragments thereof, and nucleic acids encoding same, stimulating/accelerating or downmodulating/suppressing apoptosis. For stimulation/acceleration of apoptosis, the IAPi-derived proteins or peptide fragments thereof comprise RHG and Trp-box amino acid consensus sequences. Stimulation/acceleration results in self-ubiquitination and auto-degradation of an IAP. For downmodulation/suppression of apoptosis, IAPi-derived proteins or peptide fragments thereof comprising either RHG or Trp-box amino acid consensus sequences, or both, failing to stimulate or suppressing self-ubiquitination and auto-degradation of an IAP, result in suppression of apoptosis.

Abstract: An isolated polynucleotide is provided, comprising a nucleic acid sequence encoding a soluble polypeptide which comprises an amino acid sequence of an N-terminus domain of CXCR4 and devoid of a CXCR4 extracellular domain selected from the group consisting of ECL1, ECL2 and ECL3, the soluble polypeptide being capable of binding SDF-1. Also provided are methods of using such a nucleic acid sequence such as for the treatment of cancer.

Abstract: A method of determining a coagulation status of a blood sample is provided. The method comprising determining an expression and/or activity ratio of Tissue Factor (TF) to Tissue Factor Pathway Inhibitor (TFPI) in cellular microparticles of the blood sample, wherein the ratio is indicative of the coagulation status of the blood sample.

Abstract: The invention relates to novel heparanases, heparanase splice variants, and to polynucleotides encoding them. Particularly, the invention relates to Spalax heparanases, and to Spalax and human heparanase splice variants. Heparanase splice variants can be used, for example, to modulate the activity of heparanase in diseases disorders or conditions caused by or associated with the enzymatic activity of heparanase. For instance, a splice variant capable of down regulating the activity of heparanase can be used to treat primary tumors and/or to prevent or treat metastasis.

Abstract: Propargylamine, propargylamine derivatives including N-propargyl-1-aminoindan, enantiomers and analogs thereof, and pharmaceutically acceptable salts thereof, are useful for prevention or attenuation of anthracycline-induced cardiotoxicity.

Abstract: Methods are provided for producing novel multicellular compositions comprising cancer cells together with pluripotent human stem cells, which are capable of proliferating and differentiating into various normal cell lines and tissue structures. These novel multicellular compositions are useful for investigating the properties of cancer cells in a normal human tissue microenvironment, and for studying interventions that will modulate these properties including devising, testing and screening therapeutic drugs.

Abstract: Propargylamine, propargylamine derivatives including N-propargyl-1-aminoindan and analogs thereof, and pharmaceutically acceptable salts thereof, are useful for prevention or treatment of renal failure.

Abstract: Propargylamine, propargylamine derivatives including N-propargyl-1-aminoindan, enantiomers and analogs thereof, and pharmaceutically acceptable salts thereof, are useful for prevention or treatment of cardiovascular disorders, diseases and conditions.

Abstract: A method of treating prostate cancer is provided. The method comprising administering to a subject in need thereof a therapeutically effective amount of an agent capable of reducing activity and/or expression of MCP-1 or of an effector thereof, thereby treating the prostate cancer in the subject.

Abstract: Propargylamine, propargylamine derivatives including N-propargyl-1-aminoindan and analogs thereof, and pharmaceutically acceptable salts thereof, are useful for prevention or treatment of cardiovascular disorders and diseases.

Abstract: A method of determining a potential of a diabetic patient to benefit from anti oxidant therapy for treatment of a vascular complication, the method comprising determining a haptoglobin phenotype of the diabetic patient and thereby determining the potential of the diabetic patient to benefit from said anti oxidant therapy, whereby a patient having a haptoglobin 2-2 phenotype benefits from anti oxidant therapy more than a patient having a haptoglobin 1-2 phenotype or a patient having a haptoglobin 1-1 phenotype.

Abstract: Methods for treating autoimmune diseases are provided. The methods utilize antibodies, antibody fragments or antigenic portions of IGIF or polynucleotides encoding each for inducing protective immunity against the T-cell mediated diseases in individuals having or being predisposed to such diseases.

Abstract: A method and kit of evaluating a risk of a diabetic patient to develop cardiovascular disease (CVD) is disclosed. The method comprises determining a haptoglobin phenotype of the diabetic patient and thereby evaluating the risk of the diabetic patient to develop the cardiovascular disease (CVD), wherein the risk is decreased in diabetic patients with haptoglobin 1-1 phenotype as compared to patients with haptoglobin 1-2 or haptoglobin 2-2 phenotypes. The risk is also decreased in diabetic patients with haptoglobin 1-2 phenotype as compared to patients with haptoglobin 2-2 phenotype. The kit comprises packaged reagents for determining a haptoglobin phenotype of the diabetic patient and the kit is identified for use in evaluating a risk of a diabetic patient to develop cardiovascular disease (CVD).

Abstract: A method of evaluating a risk of a subject to develop vascular complications is disclosed. The method is effected by determining a haptoglobin phenotype of the subject and thereby evaluating the risk of the subject to develop vascular complications. The risk is decreased in patients with haptoglobin 1-1 phenotype as compared to patients with haptoglobin 1-2 or haptoglobin 2-2 phenotypes.

Abstract: A method for detecting an interaction between two tester proteins. In a cell incapable of activating a Ras protein, two nucleic acid sequences are expressed. One sequence encodes for a fusion protein comprising a mutant Ras protein incapable of localizing at the cell membrane and not requiring an exchange factor fused to one of the tester proteins. The other sequence encodes for the other tester protein fused to a plasma membrane localization domain. An interaction between the two fusion proteins leads to the expression of a functional Ras protein that is tested as an altered cell phenotype.

Abstract: Novel haptoglobin derived antioxidants, nucleic acid constructs encoding same, pharmaceutical compositions containing the novel antioxidant or the nucleic acid constructs, and methods of relieving oxidative stress by administration of the antioxidants, the nucleic acid constructs encoding same or the pharmaceutical composition containing same to a subject in need thereof are disclosed.

Abstract: Disclosed are novel human and clam ubiquitin carrier polypeptides involved in the ubiquitination of cyclins A and/or B. Also disclosed are inhibitors of such polypeptides, nucleic acids encoding such polypeptides and inhibitors, antibodies specific for such polypeptides, and methods of their use.

Abstract: A method of treating rheumatoid arthritis of an individual is disclosed. The method comprises the step of expressing within the individual at least an immunologically recognizable portion of a cytokine from an exogenous polynucleotide encoding the at least a portion of the cytokine, wherein a level of expression of the at least a portion of the cytokine is sufficient to induce the formation of anti-cytokine immunoglobulins which serve for neutralizing or ameliorating the activity of a respective and/or cross reactive endogenous cytokine, to thereby treat rheumatoid arthritis.